EYEPOINT PHARMACEUTICALS INC's ticker is EYPT and the CUSIP is 30233G209. A total of 86 filers reported holding EYEPOINT PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,178,033 | -24.7% | 4,152,445 | -18.0% | 0.02% | -19.0% |
| Q2 2023 | $44,061,869 | +159.4% | 5,064,583 | -12.3% | 0.02% | +133.3% |
| Q1 2023 | $16,987,733 | -15.9% | 5,778,140 | +0.1% | 0.01% | -18.2% |
| Q4 2022 | $20,210,782 | -54.5% | 5,774,509 | +2.9% | 0.01% | -54.2% |
| Q3 2022 | $44,374,000 | +3.5% | 5,609,877 | +2.9% | 0.02% | +14.3% |
| Q2 2022 | $42,894,000 | -33.6% | 5,450,253 | +2.5% | 0.02% | -19.2% |
| Q1 2022 | $64,636,000 | +6.7% | 5,319,828 | +7.5% | 0.03% | +18.2% |
| Q4 2021 | $60,553,000 | +83.1% | 4,947,165 | +55.8% | 0.02% | +83.3% |
| Q3 2021 | $33,076,000 | +31.6% | 3,174,337 | +13.5% | 0.01% | +20.0% |
| Q2 2021 | $25,142,000 | -14.3% | 2,796,673 | -3.2% | 0.01% | -16.7% |
| Q1 2021 | $29,345,000 | +215.4% | 2,888,247 | +104.3% | 0.01% | +200.0% |
| Q4 2020 | $9,304,000 | – | 1,413,947 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Essex Woodlands Management, Inc. | 4,190,921 | $33,150,000 | 13.70% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,233,597 | $25,578,000 | 1.06% |
| ACUTA CAPITAL PARTNERS, LLC | 303,396 | $2,400,000 | 1.03% |
| Samsara BioCapital, LLC | 480,000 | $3,797,000 | 0.88% |
| Altium Capital Management LP | 224,541 | $1,776,000 | 0.65% |
| Monashee Investment Management LLC | 220,000 | $1,740,000 | 0.64% |
| RA Capital Management | 3,370,506 | $26,660,000 | 0.57% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 341,974 | $2,705,000 | 0.43% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 108,285 | $857,000 | 0.29% |
| Orbimed Advisors | 970,860 | $7,680,000 | 0.14% |